MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. ABBV
7. DFTX
8. RGNX
9. GOOGL
10. LCO

Go back to MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
MACROGENICS (NASDAQ: MGNX) Delayed: 4.10 -0.03 (0.73%)
Previous Close $4.13    52 Week High $36.11 
Open $4.01    52 Week Low $14.84 
Day High $4.13    P/E 10.51 
Day Low $4.00    EPS $0.39 
Volume 366,867